Decentralised Trials here to stay, but maybe not as many as we think.
| CONTEXT: A new report from Science 37 (a provider of Decentralised Clinical Trial (DCT) Software) based on a survey of companies from all geographies and sizes indicated that biopharma executives expect the industry to not revert entirely back to the site-based model after the changes seen during the pandemic. Whilst the report claims 80% of companies are likely to conduct some form of decentralisation this year, over 60% cited lack of internal capability to effectively operationalise any component of a DCT. READ TIME: 2 mins  1. ““This study also signals strong agreement that DCT technologies and methodologies are here to stay, and in fact, new and more agile clinical trials are likely to expand in the future,” said Coman.” 2. “LOS ANGELES–(BUSINESS WIRE)–Science 37, pioneer of the Decentralized Clinical Trial Operating System™ (DCT OS), today unveiled the DCT OS Report, which highlights the growing trend of decentralization in research and the requisite Operating System needed to effectively orchestrate stakeholder workflows, confidently generate evidence, and seamlessly harmonize data for clinical and real-world studies.” 3. “The DCT OS report, conducted by third-party Industry Standard Research (ISR), found nearly every biopharma executive surveyed expected the industry to not revert entirely back to a site-based model after advances made during the pandemic.” 4. ““The focus on data quality and the growing need to expedite clinical research timelines necessitate the activation of stakeholder networks on a seamless, unified Operating System.”” 5. “With the industry’s first and only technology-first Decentralized Clinical Trial Operating System™ (DCT OS), we enable workflow orchestration, evidence generation and data harmonization on a unified, seamless platform—configurable to enable any study and fused with our expansive networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices.” Source URL: https://www.businesswire.com/news/home/20210624005304/en/New-Science-37%C2%AE-Report-Nearly-100-of-Biopharma-Executives-Expect-Clinical-Trial-Decentralization-to-Increase-Yet-Lack-Internal-Capabilities-to-Operationalize |